Claremont CA (PRWEB) March 22, 2013
Synedgen Inc., a bio-pharmaceutical company developing novel therapies to prevent and treat infection and inflammation, announces that the United States Patent and Trademark Office (USPTO) has issued patent claims for the use of chitosan derivatives to treat or inhibit infections, and optimize animal health and weight gain to allow for the use of lower doses of antibacterial agents in animal feed. This issuance, U.S. Patent No. 8,399,635 Chitosan derivatives to treat animals or optimize animal health, continues the expansion of Synedgen’s patent portfolio.
The full patent covers methods of inhibiting the growth of or killing of bacteria, reducing bacterial load, preventing or delaying the onset of an infection, disease or disorder in an animal subject, and includes preparation, dosage and administration methods.
“The issuance of these claims enhances the strength of our growing IP portfolio,” stated Synedgen President Shenda Baker. “It describes the utility of our chitosan derivatives for infection control in food animals as well as the ability to synergize with traditional antibiotics used in their feed, dramatically reducing the amount of antibiotic used. These claims also complement the launch of Synoplex®, Synedgen’s veterinary wound rinse product designed to treat infected, chronic and non-infected wounds in elephants and rhinoceros.”
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.
Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com